language_icon
EN
HI

Sun Pharma Advanced Research Company Share price

SPARC

204.24

7.87 (4.01%)
NSE
BSE
Last updated on 2 Jun, 2026 | 15:59 IST
Today's High

207.38

Today's Low

194.10

52 Week Low

108.00

52 Week High

248.75

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Sun Pharma Advanced Research Company Chart

Sun Pharma Advanced Research Company Share Key Metrics

Volume
69.84 L
Market Cap
6627.58 CR
LTQ@LTP
100@204.24
ATP
202.27
Var Margin
100 %
Circuit Range
176.74-216
Delivery %
31.66 %
Value
141.27 CR
ASM/GSM
No
Market Lot
1

Summary

Sun Pharma Advanced Research Company share price is ₹204.24 as of 2 Jun, 2026. The stock Sun Pharma Advanced Research Company intraday movement has stayed between ₹194.10 and ₹207.38, while on a 52-week basis,Sun Pharma Advanced Research Company price 52 week high is ₹248.75 & its 52 week low is ₹108.00.
In terms of trading activity, Sun Pharma Advanced Research Company has recorded a volume of 6984191 shares, The Sun Pharma Advanced Research Company has a market cap of ₹324499558 CR. The stock’s Average Traded Price (ATP) stands at ₹202.27, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 100 @ ₹204.24.
Sun Pharma Advanced Research Company operates within a circuit range of ₹176.74 – ₹216.00, with a Value of ₹141.27 CR. The Delivery Percentage for the day is 31.66%. Additionally, Sun Pharma Advanced Research Company currently falls under the No framework, and trades with a market lot size of 1.

Sun Pharma Advanced Research Company Fundamentals

View More
P/E Ratio

4.1

P/B Ratio

4.76

Div. Yield

0

Sector P/E

25.29

Sector P/B

2.8

Sec. Div. Yield

1.37

Sun Pharma Advanced Research Company Resistance and Support

Pivot 202.4

Resistance

First Resistance

209.35

Second Resistance

222.32

Third Resistance

229.27

Support

First Support

189.43

Second Support

182.48

Third Support

169.51

Sun Pharma Advanced Research Company Shareholding Pattern

View More
  • 2016-17
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

65.67%

Mutual Fund

0.85%

Insurance

0%

Foreign Institutional Investors

2.04%

Domestic Institutional Investors

0.02%

Retail

31.42%

Others

0%

Total Promoters
MAR '26
65.67%

Sun Pharma Advanced Research Company Corporate Actions

DateAgenda
2026-05-18Audited Results
2026-02-09Quarterly Results
2026-01-14To consider issue of Warrants & ESOP
2025-11-10Quarterly Results
2025-08-04Quarterly Results
2025-05-19Audited Results
2025-02-10Quarterly Results

Sun Pharma Advanced Research Company News

Sun Pharma Advanced Research Company Ltd - 532872 - Statutory Auditors Certificate In Terms Of Regulation 169(5) Of SEBI ICDRA Regulations, 2018

Sun Pharma Advanced Research Co confirmed the receipt of Rs. 149.99 crore for a preferential allotment of 3.85 crore convertible warrants. This capital infusion strengthens the company's financial position.
May 25 2026 20:55:39

Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research confirmed receiving Rs. 149.99 crore for the preferential allotment of 3.85 crore warrants to Shanghvi Finance. The statutory auditor certified compliance with SEBI ICDR Regulations.
May 25 2026 20:39:21

Sun Pharma Advanced Research Company Ltd - 532872 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Sun Pharma Advanced Research Co's promoter group, including Shanghvi Finance Private Ltd and Persons Acting in Concert, increased their fully diluted shareholding to 69.31% by acquiring 3.85 crore warrants through a preferential allotment. These warrants, convertible into equity shares at Rs.155.80 each, signify a substantial investment by the promoter.
May 20 2026 17:18:52

Sun Pharma Advanced Research Company Ltd - 532872 - Update On PDP-716 NDA

Sun Pharma Advanced Research's licensing partner Ocuvex Therapeutics Inc. received a Complete Response Letter (CRL) from the U.S. FDA for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility, causing a delay in potential market approval.
May 19 2026 18:47:59

Sun Pharma Advanced Research Company Limited

Sun Pharma Advanced Research's licensing partner, Ocuvex Therapeutics, received a Complete Response Letter (CRL) from the U.S. FDA for the PDP-716 New Drug Application (NDA). The CRL was issued due to inspection findings at the finished product manufacturing facility.
May 19 2026 18:45:27

Sun Pharma Advanced Research Company Ltd - 532872 - Announcement under Regulation 30 (LODR)-Allotment

Sun Pharma Advanced Research Co (SPARC) has allotted 3.85 crore warrants on a preferential basis to Shanghvi Finance Private Limited at an issue price of INR 155.80 per warrant. The company has received INR 149.99 crore, representing 25% of the total warrant issue price. Each warrant is convertible into one equity share.
May 19 2026 12:42:23

Sun Pharma Advanced Research Company Ltd - 532872 - Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Financial Year Ended March 31, 2026

Sun Pharma Advanced Research Co board will convene on May 18, 2026, to consider and approve its Q4 FY26 and full-year FY26 financial results. This meeting will finalize the company's financial performance for the period ending March 31, 2026.
May 11 2026 19:05:38
Read More

Sun Pharma Advanced Research Company Management

NamePosition
Kajal DamaniaCompany Secretary & Compliance Officer
Dilip S ShanghviChairman
View More

Sun Pharma Advanced Research Company FAQs

The Buying Price of Sun Pharma Advanced Research Company share is 204.24 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Sun Pharma Advanced Research Company stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Sun Pharma Advanced Research Company, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Sun Pharma Advanced Research Company shares is 4.1. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Sun Pharma Advanced Research Company shares is 4.76. Useful to assess the stock's value relative to its book value.

To assess Sun Pharma Advanced Research Company’s valuation compare Sector P/E, P/B which are 25.29 & 2.8 with sector averages, along with growth rates and financial metrics.

The Market Cap of Sun Pharma Advanced Research Company is 6627.58 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Sun Pharma Advanced Research Company share price is 248.75 & 108.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Sun Pharma Advanced Research Company belongs to the Miscellaneous sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost